CR20210216A - Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos - Google Patents

Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos

Info

Publication number
CR20210216A
CR20210216A CR20210216A CR20210216A CR20210216A CR 20210216 A CR20210216 A CR 20210216A CR 20210216 A CR20210216 A CR 20210216A CR 20210216 A CR20210216 A CR 20210216A CR 20210216 A CR20210216 A CR 20210216A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
sulfonamide derivatives
pyridinyl sulfonamide
pyridinyl
sup
Prior art date
Application number
CR20210216A
Other languages
English (en)
Inventor
Oliver Hucke
Joerg P Hehn
Andreas Blum
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20210216A publication Critical patent/CR20210216A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a nuevos derivados de piridinil sulfonamida de la Fórmula (I) en donde R1, A y n son como se definieron en la descripción y en las reivindicaciones, a su uso como medicamentos, a métodos para su uso terapéutico y a composiciones farmacéuticas que los contienen.
CR20210216A 2018-10-29 2019-10-24 Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos CR20210216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18203196 2018-10-29
PCT/EP2019/078992 WO2020089026A1 (en) 2018-10-29 2019-10-24 Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
CR20210216A true CR20210216A (es) 2021-06-24

Family

ID=64082994

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210216A CR20210216A (es) 2018-10-29 2019-10-24 Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos

Country Status (31)

Country Link
US (1) US20210361637A1 (es)
EP (1) EP3873600B9 (es)
JP (1) JP7317109B2 (es)
KR (1) KR20210084537A (es)
CN (1) CN112955215B (es)
AU (1) AU2019373306A1 (es)
BR (1) BR112021004635A2 (es)
CA (1) CA3112510A1 (es)
CL (1) CL2021000839A1 (es)
CO (1) CO2021005509A2 (es)
CR (1) CR20210216A (es)
DK (1) DK3873600T5 (es)
DO (1) DOP2021000068A (es)
EA (1) EA202191114A1 (es)
EC (1) ECSP21030482A (es)
ES (1) ES2967359T3 (es)
FI (1) FI3873600T3 (es)
HR (1) HRP20231608T1 (es)
HU (1) HUE064995T2 (es)
IL (1) IL282428A (es)
LT (1) LT3873600T (es)
MA (1) MA54051A (es)
MX (1) MX2021004940A (es)
PE (1) PE20211467A1 (es)
PL (1) PL3873600T3 (es)
PT (1) PT3873600T (es)
RS (1) RS64963B1 (es)
SA (1) SA521421755B1 (es)
SG (1) SG11202102440SA (es)
SI (1) SI3873600T1 (es)
WO (1) WO2020089026A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873599B1 (en) * 2018-10-29 2023-09-27 Boehringer Ingelheim International GmbH Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CA3150108A1 (en) 2019-09-13 2021-03-18 Neelu Kaila HPK1 ANTAGONISTS AND THEIR USES
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
CN114621189B (zh) * 2020-12-14 2024-01-02 上海拓界生物医药科技有限公司 一种内酰胺类衍生物及其用途
CN114621190B (zh) * 2020-12-14 2023-12-05 上海拓界生物医药科技有限公司 一种烯丙基胺类衍生物及其用途
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69710921T2 (de) 1996-12-19 2002-09-19 Aventis Pharmaceuticals Inc., Bridgewater Heterocyclische substituierte pyrrolidinamid-derivate
CA2671984A1 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim International Gmbh New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
RS57086B1 (sr) 2012-05-02 2018-06-29 Boehringer Ingelheim Int Supstituisani 3-haloalilamin inhibitori ssao i njihova primena
SG11201809687TA (en) * 2016-05-12 2018-11-29 Boehringer Ingelheim Int Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
EP3873599B1 (en) * 2018-10-29 2023-09-27 Boehringer Ingelheim International GmbH Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
FI3873600T3 (fi) 2023-12-07
PE20211467A1 (es) 2021-08-05
ES2967359T3 (es) 2024-04-29
DOP2021000068A (es) 2021-06-30
HUE064995T2 (hu) 2024-04-28
SI3873600T1 (sl) 2024-02-29
EP3873600B1 (en) 2023-09-20
IL282428A (en) 2021-06-30
US20210361637A1 (en) 2021-11-25
ECSP21030482A (es) 2021-05-31
EA202191114A1 (ru) 2021-09-22
DK3873600T3 (da) 2024-01-02
CN112955215B (zh) 2024-05-17
MX2021004940A (es) 2021-06-08
CO2021005509A2 (es) 2021-05-10
DK3873600T5 (da) 2024-03-18
WO2020089026A1 (en) 2020-05-07
CN112955215A (zh) 2021-06-11
BR112021004635A2 (pt) 2021-05-25
AU2019373306A1 (en) 2021-04-08
PL3873600T3 (pl) 2024-03-11
KR20210084537A (ko) 2021-07-07
LT3873600T (lt) 2023-12-27
HRP20231608T1 (hr) 2024-03-15
EP3873600A1 (en) 2021-09-08
MA54051A (fr) 2022-02-09
SG11202102440SA (en) 2021-04-29
PT3873600T (pt) 2023-12-15
SA521421755B1 (ar) 2022-11-08
CL2021000839A1 (es) 2021-10-15
RS64963B1 (sr) 2024-01-31
EP3873600B9 (en) 2024-02-14
JP2022506198A (ja) 2022-01-17
JP7317109B2 (ja) 2023-07-28
CA3112510A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
CR20210216A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2021004000A (es) Derivados de piperidina.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
PH12021550788A1 (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
EA202092955A1 (ru) Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
ZA202203106B (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX2020014327A (es) Nuevos derivados de amino-pirimidonilo un proceso para su preparacion y composiciones farmaceuticas que los contienen.
WO2018067762A3 (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders